Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.

about

Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.

Item

http://www.wikidata.org/entity/Q50001301

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.

@en

Concordance analysis of paired cancer antigen

@nl

type

Item

label

Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.

@en

Concordance analysis of paired cancer antigen

@nl

prefLabel

Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.

@en

Concordance analysis of paired cancer antigen

@nl

P1476

Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.

@en

P2093

David C Lin

http://www.w3.org/2001/XMLSchema#string

Jonathan R Genzen

http://www.w3.org/2001/XMLSchema#string

P2860

Determination of tumor markers in serum. Pitfalls and good practice.

CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

MUC1: a multifaceted oncoprotein with a key role in cancer progression.

Tumor markers in clinical practice: General principles and guidelines.

Biochemical markers in breast cancer: which ones are clinically useful?

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers

P2888

s10549-017-4513-0

P304

269-276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4513-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28929449

http://www.w3.org/2001/XMLSchema#string